Adhering to the vision of "innovation for the great majority", Qyuns Therapeutics focuses on the research and development, industrialization and commercial expansion of antibody drugs in the fields of autoimmune and allergic diseases, and strives to solve the problems of drug accessibility and affordability.
Founded in
Pipelines
IND Approved
Patent Declared
Integrated industrial capability
The integrated research and development system we have built is the core engine of our continuous innovation, and the rabbit antibody development platform is a key link in our integrated research and development system.
Show MorePack up moreWe have established our production platform and quality management system covering the entire lifecycle of candidate drugs based on China, US and EU cGMP standards.
Show MorePack up moreContinuously exploring international expansion opportunities, looking forward to engaging in diversified strategic cooperation with potential partners, and gradually building up a small and refined in-house commercialization team.
Show MorePack up moreAD: atopic dermatitis
CRSwNP: chronic rhinosinusitis with nasal polyps
Ps: psoriasis
AS: ankylosing spondylitis
CSU: chronic spontaneous urticaria
SLE: systemic lupus erythematosus
CD: Crohn’s disease
LN: lupus nephritis
UC: ulcerative colitis
COPD: chronic obstructive pulmonary disease
PN: prurigo nodularis
IFNAR1: interferon-alpha/beta receptor subunit 1
IL-4Rα interleukin-4 receptor subunitα
IL-12/IL-23p40: interleukin-12/interleukin-23 subunit p40
IL-17A: interleukin-17A
IL-23p19: interleukin-23 subunit p19
IL-31R: interleukin-31 receptor
IL-33: interleukin-33
TSLP: thymic stromal lymphopoietin